title: Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs.
abstract: The separation of the mood-altering effects of cannabinoids from their therapeutic effects has been long sought. Results reported here for a series of C-9 analogs of the cyclic ether O,2-propano-delta 8-tetrahydrocannabinol (O,2-propano-delta 8-THC) point to the C-1 position in classical cannabinoids as a position for which CB2 subtype selectivity occurs within the cannabinoid receptors. O,2-Propano-11-delta 8-THC, O,2-propano delta 9,11-THC, O,2-propano-9-oxo-11-nor-hexahydrocannabinol (O,2-propano-9-oxo-11-nor-HHC), and O,2-propano-9 alpha- and O,2-propano-9 beta-OH-11-nor-HHC were synthesized and evaluated in radioligand displacement assays for affinity at the CB1 and CB2 receptors and in the mouse vas deferens in vitro assay and the mouse tetrad in vivo assay for cannabinoid activity. Evaluation of binding affinity at the CB1 and CB2 receptors revealed that each compound possesses a modest increased affinity for the CB2 receptor. Analogs which contained an oxygen attached to C-9 (i.e., oxo and hydroxy derivatives) showed the highest affinity and selectivity for CB2 (for O,2-propano-9-oxo-11-nor-HHC, Ki(CB1) = 90 nM, Ki(CB2) = 23 nM, selectivity ratio 3.9; for O,2-propano-9 beta-OH-11-nor-HHC, Ki(CB1) = 26 nM, Ki(CB2) = 5.8 nM, selectivity ratio 4.5). Each compound was found to produce a dose-dependent inhibition of electrically-evoked contractions of the mouse isolated vas deferens when administered at submicromolar concentrations. This inhibition could readily be prevented by the selective CB1 cannabinoid receptor antagonist SR-141716A. The analogs exhibited unique in vivo profiles with O,2-propano-delta 9,11-THC exhibiting antinociception with reduced activity in three other in vivo measures and O,2-propano-9 beta-OH-HHC exhibiting lack of dose responsiveness in all measures. The CB2 selectivities in the O,2-propano analogs may be due to differences in solvation/desolvation that occur when the ligands enter the CB1 vs CB2 binding site. Alternatively, the CB2 selectivities may be a results of an amino acid change from a hydrogen bond-accepting residue in CB1 to a hydrogen bond-donating residue in CB2.
authors.affiliation: Department of Chemistry, Kennesaw State University, Georgia 30144, USA.
authors.forename: P H
authors.initials: PH
authors.lastname: Reggio
authors.forename: T
authors.initials: T
authors.lastname: Wang
authors.forename: A E
authors.initials: AE
authors.lastname: Brown
authors.forename: D N
authors.initials: DN
authors.lastname: Fleming
authors.forename: H H
authors.initials: HH
authors.lastname: Seltzman
authors.forename: G
authors.initials: G
authors.lastname: Griffin
authors.forename: R G
authors.initials: RG
authors.lastname: Pertwee
authors.forename: D R
authors.initials: DR
authors.lastname: Compton
authors.forename: M E
authors.initials: ME
authors.lastname: Abood
authors.forename: B R
authors.initials: BR
authors.lastname: Martin
mesh_terms: D000818:Animals; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000378:metabolism; D007536:Isomerism; D051379:Mice; D008956:Models, Chemical; D009619:Nociceptors / Q000187:drug effects; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000378:metabolism*; D013329:Structure-Activity Relationship
chemical_list: D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; D013759:Dronabinol